Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand

Published:2024-06 Issue: Volume:143 Page:107021
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Salvadori Nicolas^ORCID,Jourdain Gonzague,Krittayaphong Rungroj,Siripongboonsitti Taweegrit^ORCID,Kongsaengdao Subsai,Atipornwanich Kriangsak,Sakulkonkij Parichart,Angkasekwinai Nasikarn,Sirijatuphat Rujipas,Chusri Sarunyou,Mekavuthikul Tanavit,Apisarnthanarak Anucha,Srichatrapimuk Sirawat,Sungkanuparph Somnuek^ORCID,Kirdlarp Suppachok^ORCID,Phongnarudech Thanyakamol,Sangsawang Suraphan,Napinkul Panuwat,Achalapong Jullapong,Khusuwan Suwimon,Pratipanawat Piyanut,Nookeu Pornboonya,Danpipat Namphol,Leethong Pornvimol,Hanvoravongchai Piya,Sukrakanchana Pra-ornsuda^ORCID,Auewarakul Prasert^ORCID

Funder

National Science and Technology Development Agency

Publisher

Elsevier BV

Reference24 articles.

1. Therapeutics and COVID-19: Living guideline, 13 January 2023,2023

2. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines, Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf [accessed 9 October, 2023].

3. Early remdesivir to prevent progression to severe Covid-19 in outpatients;Gottlieb;N Engl J Med,2022

4. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients;Jayk Bernal;N Engl J Med,2022

5. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP